Related by context. All words. (Click for frequent words.) 79 chemotherapy regimens 72 chemotherapy 69 chemotherapies 68 docetaxel chemotherapy 68 temozolomide 67 chemoradiation 67 docetaxel 66 cisplatin 66 cyclophosphamide 66 chemotherapeutic regimens 66 gemcitabine 65 etoposide 64 neoadjuvant chemotherapy 64 sunitinib 64 dacarbazine 64 cetuximab 64 trastuzumab 64 adjuvant therapy 64 fluorouracil 64 standard chemotherapy regimen 64 rituximab 63 regimens 63 advanced NSCLC 63 FOLFIRI 63 5 fluorouracil 63 treatment regimens 63 taxane chemotherapy 63 bevacizumab 63 Doxil ® 63 irinotecan 63 topotecan 63 gemcitabine chemotherapy 63 bevacizumab Avastin 62 fludarabine 62 hormonal therapy 62 tamoxifen therapy 62 mitoxantrone 62 DMARD 62 adjuvant chemotherapy 62 chemotherapy docetaxel 62 carboplatin paclitaxel 62 HAART regimen 62 DMARD therapy 62 chemoradiotherapy 62 metastatic colorectal cancer 62 chemo radiotherapy 62 preoperative chemotherapy 62 carboplatin 62 bortezomib 61 nab paclitaxel 61 pegylated interferon 61 oxaliplatin 61 paclitaxel Taxol R 61 gemcitabine Gemzar 61 standard chemotherapy regimens 61 antiretroviral regimens 61 interferon therapy 61 capecitabine 61 CHOP chemotherapy 61 5 FU 61 metastatic renal cell carcinoma 61 erlotinib 61 5FU 61 relapsed ovarian cancer 61 Cytoxan 61 pegylated liposomal doxorubicin 61 antiretroviral regimen 61 chemo 61 cytotoxic chemotherapy 61 trastuzumab Herceptin ® 61 TACE 61 sorafenib 61 imatinib 61 DMARDs 60 heavily pretreated patients 60 pemetrexed 60 FOLFOX 60 HER2 positive metastatic breast 60 chlorambucil 60 idarubicin 60 mycophenolate mofetil 60 epirubicin 60 methotrexate 60 relapsed 60 anthracycline taxane 60 irinotecan chemotherapy 60 adriamycin 60 peginterferon 60 anthracyclines 60 superficial bladder cancer 60 taxane therapy 60 trabectedin 60 chemotherapeutic agent 60 dasatinib 60 cisplatin chemotherapy 60 Cisplatin 60 docetaxel Taxotere 60 indolent NHL 60 azathioprine 60 FOLFOX4 60 brain metastases 60 Taxotere 60 anthracycline 59 5-FU/LV 59 ribavirin RBV 59 antidepressant therapy 59 gemcitabine carboplatin 59 metastatic SCCHN 59 paclitaxel carboplatin 59 chemotherapy cisplatin 59 TNF inhibitor 59 metastatic breast cancer 59 leucovorin 59 peg IFN 59 NSCLC 59 vinorelbine 59 postoperative chemotherapy 59 metastatic colon cancer 59 exemestane 59 cytarabine 59 cytotoxic therapy 59 regimen 59 alkylating agent 58 adalimumab 58 methotrexate therapy 58 dose regimen 58 metastatic RCC 58 azacitidine 58 paclitaxel Taxol 58 dose regimens 58 Pemetrexed 58 virologic failure 58 lamivudine 58 temsirolimus 58 curative resection 58 sorafenib Nexavar 58 interferon alfa 58 bendamustine 58 vandetanib 58 low dose cytarabine 58 Fludara 58 mRCC 58 tamoxifen 58 pegylated interferon alfa 58 HER2 positive breast cancer 58 sorafenib Nexavar ® 58 antihypertensive therapy 58 Doxil 58 chemotherapy gemcitabine 58 fulvestrant 58 imatinib Gleevec 58 XELOX 58 Taxotere ® 58 cytoreduction 58 liposomal doxorubicin 58 mCRC patients 58 dosing regimens 58 interferon alfa 2a 58 decitabine 58 dose cytarabine 57 recurrent GBM 57 pomalidomide 57 BEACOPP 57 chemotherapeutic regimen 57 dose escalation 57 infliximab 57 free survival PFS 57 bevacizumab Avastin ® 57 olaparib 57 dosing schedules 57 radiochemotherapy 57 abiraterone 57 pazopanib 57 neoadjuvant therapy 57 ribavirin therapy 57 chemotherapeutic agents 57 doxorubicin 57 eribulin 57 dose dexamethasone 57 mitoxantrone chemotherapy 57 gefitinib 57 docetaxel prednisone 57 GnRH agonists 57 cabazitaxel 57 adjuvant radiation 57 alkylating agents 57 Bevacizumab 57 peginterferon alfa 2a 57 remission induction 57 Gleevec imatinib 57 liver metastases 57 virological failure 57 refractory multiple myeloma 57 dexamethasone 57 non squamous NSCLC 57 mitomycin 57 doxorubicin HCl liposome injection 57 paclitaxel chemotherapy 57 Cyclophosphamide 57 breast irradiation 57 Fludarabine 57 relapsed MM 57 APTIVUS r 57 protease inhibitor PI 57 Irinotecan 57 relapsed refractory 57 oral clodronate 57 pegylated interferon alpha 57 neoadjuvant 57 daunorubicin 57 lapatinib 57 diagnosed multiple myeloma 57 letrozole 57 paclitaxel Taxol ® 57 cytoreductive surgery 57 NRTIs 56 Chemotherapy 56 panitumumab 56 prostate cancer HRPC 56 pegfilgrastim 56 imatinib therapy 56 SCCHN 56 taxane 56 plus ribavirin 56 infusional 5-FU/LV 56 PegIFN RBV 56 TTF Therapy 56 Platinol ® cisplatin 56 bisphosphonate therapy 56 concurrent chemoradiation 56 lapatinib Tykerb 56 plus dexamethasone 56 mapatumumab 56 induction regimen 56 NNRTI 56 Xeloda 56 mCRC 56 therapeutic regimens 56 intravenous chemotherapy 56 stage IIIB 56 Mylotarg 56 iniparib 56 hormonal therapies 56 refractory CTCL 56 MabCampath 56 resistant ovarian cancer 56 chronic lymphocytic leukemia CLL 56 colorectal liver metastases 56 surgical debulking 56 sustained virologic response 56 Adriamycin 56 pegylated interferon alfa 2a 56 raltegravir 56 peg interferon 56 platinum refractory 56 IV bolus 56 myeloablative 56 dosage regimens 56 Sunitinib 56 tumor shrinkage 56 abiraterone acetate 56 heavily pretreated 56 #mg/m# [002] 56 Carboplatin 56 PREZISTA r 56 telaprevir dosed 56 IV NSCLC 56 leukemia CLL 56 boosted protease inhibitor 56 Dose escalation 56 Platinol ® 56 microwave hyperthermia 56 steroid prednisone 56 aromatase inhibitor 56 ABVD 56 gefitinib Iressa 56 melphalan prednisone 56 cyclophosphamide Cytoxan 56 metastatic squamous cell carcinoma 56 HSCT 56 recurrent NSCLC 56 arsenic trioxide 56 hormone refractory prostate cancer 56 Torisel 56 gemcitabine cisplatin 56 intraperitoneal chemotherapy 56 differentiated thyroid 56 paclitaxel 56 recurrent glioblastoma multiforme 56 protease inhibitor 56 Adjuvant chemotherapy 56 cyclophosphamide methotrexate 56 relapsed refractory multiple myeloma 55 fluvastatin 55 FOLFOX regimen 55 chemoradiation therapy 55 dose cohorts 55 PegIntron 55 interferon 55 follicular NHL 55 Gemcitabine 55 follicular lymphoma 55 care regimens CCR 55 EBRT 55 anti leukemic 55 IMGN# 55 refractory CLL 55 ELOXATIN 55 ribavirin 55 Response Evaluation Criteria 55 docetaxel Taxotere R 55 trastuzumab Herceptin 55 intrathecal chemotherapy 55 Peg IFN 55 IV metastatic melanoma 55 HAART regimens 55 Halaven 55 CANCIDAS 55 antiplatelet therapy 55 androgen ablation 55 immunosuppressive agents 55 doxorubicin cyclophosphamide 55 relapsing MS 55 endocrine therapy 55 ethambutol 55 VIDAZA 55 Erlotinib 55 dexamethasone Decadron 55 metastatic hormone refractory 55 vincristine 55 hepatic metastases 55 metastatic CRC 55 adjuvant tamoxifen 55 relapsed CLL 55 melphalan 55 recurrent ovarian cancer 55 zoledronic acid 55 interferon ribavirin 55 Revlimid lenalidomide 55 androgen deprivation 55 multiple myeloma 55 cediranib 55 cytarabine daunorubicin 55 monotherapy 55 cART 55 myelodysplastic syndrome MDS 55 KRAS status 55 disease modifying antirheumatic 55 unresectable 55 lenalidomide Revlimid R 55 Taxotere R 55 intravenous infusion 55 fluoropyrimidine 55 overlapping toxicities 55 3TC lamivudine Epivir 55 estramustine 55 alfa 2a 55 COPAXONE ® 55 ritonavir boosted 55 malignant pleural mesothelioma 55 Folfox 55 temozolomide TMZ 55 leukemia AML 55 docetaxel Taxotere ® 55 stem cell transplant 55 virologic response 55 immunosuppressant 55 metastatic lung cancer 55 Amrubicin 55 radiation therapy SBRT 55 Methotrexate 55 Herceptin trastuzumab 55 statin therapy 55 sunitinib malate 55 paricalcitol 55 fallopian tube carcinoma 54 Velcade bortezomib 54 prior chemotherapy regimens 54 dacarbazine chemotherapy 54 FOLFOX6 54 pneumonectomy 54 metastatic NSCLC 54 Trastuzumab 54 refractory ovarian cancer 54 VICTRELIS 54 axitinib 54 relapsing multiple sclerosis 54 neoadjuvant treatment 54 rFVIIa 54 debulking surgery 54 erlotinib Tarceva ® 54 lymph node dissection 54 taxanes 54 anastrozole 54 Platinol 54 trans retinoic acid ATRA 54 low dose dexamethasone 54 bleomycin 54 warfarin therapy 54 dosing cohort 54 lupus nephritis 54 epirubicin cyclophosphamide 54 Mitoxantrone 54 chemo treatments 54 Ceplene/IL-2 54 thalidomide Thalomid 54 letrozole Femara 54 induce remission 54 isoniazid 54 Doxorubicin 54 REVLIMID 54 chemotherapy treatments 54 ER CHOP 54 colectomy 54 metastatic kidney 54 NRTI 54 pegylated interferon peg IFN 54 imetelstat 54 folinic acid 54 immunosuppressive regimen 54 external beam radiotherapy 54 intravenous antibiotic 54 RECIST criteria 54 neurologic progression 54 atazanavir 54 relapsed myeloma 54 ZOLINZA 54 Vectibix 54 cyclophosphamide doxorubicin vincristine 54 nephrectomy 54 Capecitabine 54 therapy 54 nilotinib 54 5 FU leucovorin 54 Taxol paclitaxel 54 Tamoxifen 54 refractory AML 54 uric acid lowering 54 placebo dexamethasone 54 antiretroviral therapy 54 tumor recurrence 54 Navelbine ® 54 abatacept 54 FOLFIRINOX 54 #mg/m# [001] 54 Jevtana 54 ixabepilone 54 rituximab Rituxan 54 follicular non 54 nonsmall cell lung cancer 54 Oxaliplatin 54 pertuzumab 54 biologic therapy 54 renal cell carcinoma 54 HAART 54 colorectal cancer liver metastases 54 DAPT 54 cetuximab Erbitux R 54 tyrosine kinase inhibitor 54 HGS# 54 enfuvirtide 54 RESIST studies 54 radiotherapy SBRT 54 bicalutamide 54 KRAS wild 54 radiation chemoradiation 54 doxorubicin docetaxel 54 tyrosine kinase inhibitors 54 TKI therapy 54 antiviral therapy 54 cilengitide 54 cystectomy 54 iniparib BSI 54 Xcytrin 54 APTIVUS 54 radiation therapy 54 immunosuppressive regimens 54 paroxysmal AF 54 goserelin 54 Lapatinib 54 exemestane Aromasin 54 taxotere 54 gastrointestinal stromal tumor GIST 53 castration resistant prostate cancer 53 mg/m2 dose 53 prostate cancer CRPC 53 ritonavir boosted lopinavir 53 pancreatic NET 53 intravenous bisphosphonates 53 FOLFOX chemotherapy 53 clinically localized prostate 53 dose clopidogrel 53 allogeneic stem cell 53 grade gliomas 53 platelet transfusions 53 MGd 53 Sorafenib 53 Flu Cy 53 vorinostat 53 PEGINTRON TM 53 radical nephrectomy 53 Hycamtin 53 Zolinza 53 recurrent prostate cancer 53 relapsing remitting 53 dosing regimen 53 metastatic castration resistant 53 ritonavir boosted protease inhibitor 53 Bortezomib 53 PSADT 53 Cetuximab 53 erlotinib Tarceva 53 TORISEL 53 Rituximab 53 CoFactor 53 metastatic CRPC 53 nelfinavir 53 nevirapine Viramune 53 irbesartan 53 levodopa therapy 53 metastatic disease 53 pyrazinamide 53 T DM1 53 omalizumab 53 axillary dissection 53 anthracyclines taxanes 53 radiofrequency ablation RFA 53 phase IIb trial 53 bortezomib Velcade 53 aromatase inhibitor therapy 53 efavirenz Sustiva 53 dosing intervals 53 enzastaurin 53 resectable 53 VELCADE melphalan 53 PREZISTA rtv 53 epithelial ovarian cancer 53 AGILECT R 53 Camptosar 53 anti TNF 53 Cremophor 53 refractory NSCLC 53 Paraplatin ® 53 hormone receptor positive 53 efavirenz EFV 53 dacarbazine DTIC 53 radiotherapy 53 SBRT 53 autologous transplant 53 prednisone 53 q#h 53 entecavir 53 dasatinib Sprycel ® 53 paclitaxel cisplatin 53 detectable HCV RNA 53 mcg kg 53 relapsed SCLC 53 relapsing remitting multiple sclerosis 53 eptifibatide 53 relapsed multiple myeloma 53 efficacy endpoint 53 lenalidomide 53 Anthracycline 53 capecitabine Xeloda R 53 Sutent 53 operable breast cancer 53 dosing cohorts 53 mcg albinterferon alfa 2b 53 DOXIL 53 interferon alfa 2b 53 PEGINTRON 53 WBRT 53 KRAS mutations occur 53 androgen suppression therapy 53 Femara 53 HRPC 53 Bezielle 53 intra arterial chemotherapy 53 prophylactic cranial irradiation 53 cisplatin carboplatin 53 relapsing remitting MS 53 sentinel lymph node biopsy 53 dasatinib Sprycel 53 invasive candidiasis 53 oblimersen 53 locoregional recurrence 53 FluCAM 53 lipid lowering therapy 53 INTELENCE 53 null responders 53 levosimendan 53 YONDELIS 53 aflibercept VEGF Trap 53 acute myelogenous leukemia AML 53 leflunomide 53 Novantrone 53 sevelamer 53 receptor tyrosine kinase inhibitor 53 previously untreated follicular 53 IRESSA 53 Tarceva erlotinib 53 acute STEMI 53 regorafenib 53 metastatic prostate cancer 53 ipilimumab 53 cidofovir 53 androgen deprivation therapy 53 TKIs 53 pegylated interferon alfa 2b 53 pancreatic adenocarcinoma 53 EGFR TKI 53 nitazoxanide 53 plus gemcitabine 53 FOLPI regimen 53 antithymocyte globulin 53 recurrent metastatic 53 thalidomide dexamethasone 53 Hodgkin lymphoma NHL 53 plus prednisone 53 surrogate endpoint 53 antibiotic regimens 53 Dasatinib 52 KRAS mutant tumors 52 PROSTVAC ® 52 Vidaza 52 intravenous cyclophosphamide 52 vicriviroc 52 chemotherapeutic drug 52 mastectomy chemotherapy 52 disease progression 52 subgroup analyzes 52 d4T 52 rindopepimut 52 Aromasin 52 cetuximab Erbitux ® 52 stage IIIb IV 52 darunavir ritonavir 52 clopidogrel 52 dose dose escalation 52 epoetin alfa 52 randomized multicenter Phase III 52 carfilzomib 52 stage IIIB IV 52 locoregional 52 zidovudine lamivudine 52 nilotinib Tasigna ® 52 Docetaxel 52 #mg dose [003] 52 DOXIL ® 52 Revlimid 52 allogeneic transplant 52 trastuzumab Herceptin R 52 adjuvant radiotherapy 52 progression TTP 52 FIRMAGON 52 Hydroxyurea 52 capecitabine Xeloda 52 fondaparinux 52 5-fluorouracil/leucovorin 52 cell lymphoma CTCL 52 metastatic malignant melanoma 52 adalimumab Humira 52 chemotherapeutic 52 amoxicillin clavulanate 52 lenalidomide dexamethasone 52 dose cyclophosphamide 52 immunomodulatory therapy 52 Neoadjuvant 52 xenograft models 52 hepatectomy 52 Metastatic breast cancer 52 antithrombotic therapy 52 Avastin bevacizumab 52 ASCT 52 neostigmine 52 stavudine 52 TEMODAL 52 cell lung cancer 52 transarterial chemoembolization 52 Cloretazine 52 elacytarabine 52 COPAXONE R 52 Gleevec 52 autologous stem cell 52 Paraplatin ® carboplatin 52 amphotericin B 52 unfractionated heparin 52 peginterferon alfa 2a Pegasys 52 Tykerb 52 Dacogen 52 Xelox 52 sulfasalazine 52 Arsenic trioxide 52 pegylated alpha interferon 52 hydroxychloroquine 52 hormonal treatments 52 mycophenolate mofetil MMF 52 refractory SCLC 52 anthracycline therapy 52 steroid dexamethasone 52 EGFR tyrosine kinase inhibitors 52 AZILECT 52 mycosis fungoides 52 Copegus ribavirin 52 Sutent sunitinib 52 adjuvant endocrine therapy 52 SCIg 52 Taxotere chemotherapy 52 achieve sustained virologic 52 5 Fluorouracil 52 cytotoxic agents 52 Pixantrone 52 hormone deprivation 52 androgen suppression 52 median PFS 52 allopurinol 52 abacavir lamivudine 52 BEXXAR 52 farletuzumab 52 adefovir 52 Avastin 52 cisplatin gemcitabine 52 imatinib resistant 52 glioblastoma 52 deferiprone 52 BRAF inhibitor 52 figitumumab 52 immunosuppression 52 MyVax R 52 GnRH agonist 52 RRMS patients 52 recurrent glioblastoma 52 randomized Phase III 52 stereotactic body 52 cranial radiation 52 sentinel node biopsy 52 basal insulin 52 antibiotic therapy 52 Gemzar ® 52 lung metastases 52 systemic ALCL 52 pCR 52 unstable angina UA 52 B CLL 52 clopidogrel Plavix 52 Median survival 52 CsA 52 Faslodex 52 immunosuppressive medications 52 complete remissions 52 metformin 52 FOLPI 52 tacrolimus 52 chemo therapy 52 intraperitoneal therapy 52 seminoma 52 intravenous diuretics 52 plasma uric acid 52 peginterferon alpha 2a 51 rt PA 51 bone metastases 51 Allovectin 7 ® 51 dual antiplatelet therapy 51 SUTENT 51 allogeneic SCT 51 metastatic melanoma 51 CA4P 51 tenecteplase 51 flutamide 51 Femara letrozole 51 CR# vcMMAE 51 Bexxar 51 immunosuppressant drug 51 Temsirolimus 51 efalizumab 51 chemotherapy FOLFOX 51 virological response 51 amrubicin 51 potentially hepatotoxic 51 sunitinib sorafenib 51 corticosteroid dexamethasone 51 galiximab 51 orchiectomy 51 hormone therapy 51 levodopa 51 ACE inhibitor 51 axillary node dissection 51 platelet inhibitor 51 alvespimycin 51 mealtime insulin 51 Combination therapy 51 bolus dose 51 phosphate binders 51 pegylated interferon alpha 2a 51 trials RCTs 51 ascending doses 51 methotrexate monotherapy 51 beta blocker atenolol 51 TNF inhibitors 51 PSMA ADC 51 diagnosed glioblastoma multiforme 51 cholinesterase inhibitor 51 hypomethylating agents 51 N acetylcysteine 51 pyridostigmine 51 remission CR 51 administered subcutaneously 51 metastatic HRPC 51 Rituxan rituximab 51 Telintra 51 Zevalin consolidation 51 oral antidiabetes drugs 51 grade glioma 51 Clolar 51 visilizumab 51 etanercept 51 partial remissions 51 mg/m2/day 51 Riluzole 51 AVASTIN 51 BAY #-# 51 antiangiogenic therapy 51 candesartan 51 Telcyta 51 infliximab Remicade 51 β blockers 51 bronchial thermoplasty 51 gout flares 51 aflibercept 51 CellCept 51 eribulin mesylate 51 CVP chemotherapy 51 PLX# 51 antidepressant medication 51 LIALDA 51 drug DMARD 51 mg kg dose 51 anthracycline chemotherapy 51 trans retinoic acid 51 Bacillus Calmette Guerin BCG 51 durable remissions 51 dexpramipexole 51 anakinra 51 phase IIb clinical 51 evaluating Xcytrin 51 pregabalin 51 conventional DMARDs 51 metastatic cancer 51 DLBCL 51 oral rivaroxaban 51 FASLODEX 51 hepatitis C genotype 51 Gefitinib 51 ovarian stimulation 51 chemotherapy radiotherapy 51 antihypertensive medications 51 EGFR expressing mCRC 51 FOLFIRI alone 51 DMARDS 51 localized prostate cancer 51 antiandrogen 51 pramlintide 51 HBeAg negative 51 darunavir 51 liver transplant recipients 51 olmesartan 51 nonmetastatic prostate cancer 51 cinacalcet 51 DFMO 51 GVAX 51 Peginterferon 51 ponatinib 51 Treanda 51 glufosfamide 51 eplerenone 51 oral prednisone 51 breast carcinoma 51 Genasense 51 follicular lymphoma FL 51 unresectable stage 51 advanced unresectable 51 peritoneal cancer 51 relapsed AML 51 ALA PDT 51 3TC 51 gastrointestinal stromal tumors GIST 51 serous ovarian cancer 51 VELCADE 51 epirubicin cisplatin 51 immunosuppressant drugs 51 basal cell carcinoma BCC 51 Adjuvant therapy 51 HCV genotype 1 51 MDS AML 51 Xeloda capecitabine 51 mg/m2 51 thrombolytic therapy 51 tigecycline 51 EGFR mutation 51 refractory HL 51 immunosuppressive drugs 51 aspirin clopidogrel 51 clomipramine 51 glucose lowering 51 untreated CLL 51 Elitek 51 Degarelix 51 Gleevec resistant 51 liposomal formulation 51 imatinib Gleevec ® 51 squamous histology 51 acute gout flares 51 eflornithine 51 indolent lymphomas 51 EGFR expressing 51 assessing T DM1 51 BENICAR HCT 51 thymic carcinoma 51 pamidronate 51 insulin detemir 51 metastatic pancreatic cancer 51 antihypertensive agents 51 4mg/kg 51 infusional 51 Rituxan 51 glatiramer acetate Copaxone 51 Retreatment 51 severe neutropenia 51 Free Survival PFS 51 pimecrolimus 51 liver biopsies 51 lintuzumab 51 chemotherapeutic drugs 51 systemic corticosteroids 51 zidovudine 51 nucleoside analogue 51 intravesical therapy 51 baminercept 51 idraparinux 51 anthracycline containing 51 indolent lymphoma 51 anti androgen 51 sipuleucel T 51 dose melphalan 51 HER2 positive 51 Pegintron 51 lymphadenectomy 51 epoetin beta 51 doublet chemotherapy 51 placebo controlled trials 51 myelodysplastic syndromes MDS 51 chronic GVHD 51 biologic DMARD 51 NATRECOR R 51 PegIFN 51 Naive Patients 51 azacytidine 51 Pegasys ® 51 complete cytogenetic 51 glioblastoma multiforme GBM 51 conventional IMRT 51 Neulasta ® 51 milatuzumab 51 alpha 2a 51 Traficet EN 51 genotypic resistance 51 BENICAR 51 Pertuzumab 50 fibrinolytic 50 anti TNF alpha 50 mercaptopurine 50 salmeterol fluticasone 50 PSA nadir 50 #mg dose [001] 50 adverse cytogenetics 50 lopinavir r 50 H. pylori eradication 50 evaluable patients 50 anti angiogenic agents 50 vincristine doxorubicin 50 antiretroviral therapy ART 50 thyroidectomy 50 ganetespib 50 basiliximab 50 tipranavir 50 alefacept 50 nonresponders 50 cytogenetic response 50 dose titration 50 chemotheraphy 50 biochemical relapse 50 Revimmune 50 beta blocker therapy 50 imatinib mesylate Gleevec 50 Taxotere docetaxel 50 glioblastomas 50 tyrosine kinase inhibitors TKIs 50 NRTI backbone 50 Kantarjian